Caribou Biosciences (CRBU) Expected to Announce Quarterly Earnings on Monday

Caribou Biosciences (NASDAQ:CRBU) is projected to post its quarterly earnings results before the market opens on Monday, March 10th. Analysts expect Caribou Biosciences to post earnings of ($0.40) per share for the quarter.

Caribou Biosciences Price Performance

Shares of Caribou Biosciences stock opened at $1.16 on Friday. The stock’s fifty day moving average is $1.43 and its two-hundred day moving average is $1.82. The company has a market capitalization of $105.04 million, a PE ratio of -0.70 and a beta of 2.34. Caribou Biosciences has a 52 week low of $1.01 and a 52 week high of $7.61.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Bank of America cut their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Citigroup lowered their target price on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $9.00 target price on shares of Caribou Biosciences in a report on Friday, November 15th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Caribou Biosciences presently has a consensus rating of “Buy” and a consensus price target of $10.33.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.